Wednesday, July 19, 2017 – Noon-1:30 p.m.Russell Senate Office Building, Room 485 – U.S. Capitol Hill
One of the most promising areas of cancer research is the field of immuno-oncology. Scientists are discovering new ways to arm a patient’s immune system so that it can attack cancer cells, and the result has been one of the most transformative approaches to cancer treatment that has ever entered the clinic. For many patients, cancer immunotherapies are already providing life-saving results where other treatments had failed or were not viable. But realizing more breakthroughs in this area and broadening the scope of cancers that can be treated with immuno-oncology requires a sustained, federal investment in cancer research through the National Institutes of Health and the National Cancer Institute.
The American Association for Cancer Research and the Society for Immunotherapy of Cancer are pleased to host this briefing that will highlight some of the exciting innovations that are being delivered through immuno-oncology, illustrate the hope that these advances are bringing to patients, and note the challenges that still need to be overcome so that even more patients can benefit from these revolutionary treatments.
AACR and SITC cordially invite you to this Congressional briefing. Register online. Also, download this informational flyer (PDF).
After the briefing: Join SITC and AACR leaders in a Facebook Live event at 2 p.m. ET on July 19 via the AACR Facebook feed as they answer questions and discuss the impact of the day's briefing.
The Society for Immunotherapy of Cancer (SITC) strongly opposes the proposed budget cuts to federal scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 budget request.
This proposal calls for a reduction in funding for the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of its total budget. If applied proportionally across NIH, funding for the National Cancer Institute (NCI) would be curtailed by nearly $1 billion. If enacted, these cuts will jeopardize years of progress being made on accelerating cancer research, education, prevention and treatment.
Read more of this SITC statement in Press Releases.
If you have partnership or policy-related questions, please contact SITC staff at SITCExecOffice@sitcancer.org.
On March 23, 2017, SITC joined 26 other organizations in a letter directed to leaders of the U.S. House of Representatives in strong opposition to the proposed repeal of the indoor tanning tax that was included in the American Health Care Act (AHCA).
To read the full letter, click here.
The Immuno-Oncology Policy Working Group launched in December 2015 to develop a strategic policy plan to accelerate progress for immune-oncology in multiple disease types and settings. SITC is co-leading this initiative, joining Friends of Cancer Research, EMD Serono and Pfizer.
Immuno-oncology (I-O) has been fueled by numerous clinical trial successes in recent years and has already transformed traditional approaches to cancer treatment. The I-O Policy Working Group develops policy strategies to facilitate the development and use of immuno-oncology treatments including regulatory, legislative, reimbursement and education/training efforts.
Broadly, outstanding challenges fall into two categories: scientific, related to furthering our understanding of the mechanisms that drive immunotherapy, and systemic, related to ensuring these therapies are appropriately used as single agents or in combination in the clinical setting. At a time when mainstream adoption of I-O is still taking hold, an opportunity exists to learn from early experiences with I-O in melanoma and lung cancer, and identify and address high priority policy-related issues defined by the emerging science.
While many of the challenges will be addressed as our understanding of the mechanisms of action behind immune-oncology develop, there is a role for the multi-stakeholder community to facilitate development of and appropriate access to those scientific discoveries by leveraging and mobilizing our collective knowledge to support innovation in immune-oncology.
The output of this effort is informed by recent advancements in research, intended to be outcome-driven, and designed to leverage and complement other ongoing activities in the field.
Learn more about the participating constituencies of the I-O Policy Working Group.
On December 7, 2016, the U.S. Senate approved the 21st Century Cures Act, a wide-ranging health bill whose passage ensured the American government's commitment to curing cancer. President Barack Obama signed the bill into law soon there after.
The 21st Century Cures Act, sponsored by U.S. Rep. Fred Upton (R-MI), invests more than $6.5 billion in a variety of healthcare initiatives, including funding for cancer research. Among the ways it will affect our field’s future is enhancing the ability to more effectively use large volumes of data toward clinical advancements in cancer research, spark development of precision medicine, and accelerates the pace of clinical trials through the required use of centralized institutional review boards.
SITC joined 20 other cancer-focused organizations in a letter publicly declaring support for the Cures Act.
The letter – sent by the NCCR, an advocacy companion organization of the National Coalition for Cancer Research – stressed the critical importance of the bill, including investing in the future of biomedical research with an emphasis on promoting young investigators in the cancer research field.
Click here to read the NCCR letter.
In January 2016, then-President Barack Obama announced a $1B National Cancer Moonshot Initiative. The initiative, led by former Vice President Joe Biden, aims to accelerate research efforts and break down barriers to progress by enhancing data access, and facilitating collaborations with researchers, doctors, philanthropies, patients, and patient advocates, and biotechnology and pharmaceutical companies. The overarching goal is to bring about a decade’s worth of advances in five years, making more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage.
Vice President Biden is moving forward with his efforts to focus upon ending cancer as a part of his priorities during his last year in office and beyond. Immunotherapy, genomics and combination therapies are central to these research efforts.
Throughout 2016, SITC leaders participated in the Cancer Moonshot as the collective voice for the field of cancer immunotherapy. SITC involvement has taken shape in the following ways:
On June 29, 2016, Biden convened a Cancer Moonshot Summit in Washington, D.C. SITC was represented by the society's Executive Director, Tara Withington, CAE along with other SITC members in attendance. In connection with the D.C. summit, SITC hosted a virtual Twitter summit to foster discussion amongst members, colleagues, patients, and advocates.
On October 17, 2016, Biden delivered the Cancer Moonshot report to the President and the American public. The report summarizes the work of the Cancer Moonshot Task Force since its creation in January, and lays out the Vice President’s strategic plan for transforming cancer research and care. The report also includes the Cancer Moonshot Blue Ribbon Panel’s identified areas of scientific opportunity. SITC leaders including Executive Director Tara Withington, CAE were in attendance onsite.
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients. In this exclusive interview with Oncology Central, ...
Chimeric antigen receptor (CAR) T cell therapy shows effectiveness against hematologic malignancies, particularly, against B-cell acute lymphoblastic leukemia in clinical trials. But is also to be enhanced for solid cancers. CARs can increase tumor specificity ...
I've seen a couple of patients on doses of prednisone as high as 40 BID with complete responses to PD-1/PD-L1 therapy. I'm not aware of robust data that shows steroids reduce efficacy. The largest study on this that I'm aware of found no difference in ...
Postdoctoral Fellow – T-cell Immunology and Viral Diseases Job #1458BR
Center for Chemical Biology Menlo Park, CA
The cited article makes the following statements on the impact of immune-related adverse events and immunosupression on efficacy with respect to checkpoint inhibitor therapy. 1. Immunosuppressive agents to treat immune-related adverse events do not appear ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com